Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine

@article{Santos2004HepatitisBV,
  title={Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine},
  author={Eneida Almeida Santos and Michel V F Sucupira and Juçara Arabe and Selma A Gomes},
  journal={BMC Infectious Diseases},
  year={2004},
  volume={4},
  pages={29 - 29}
}
BACKGROUND Lamivudine inhibits replication of both human immunodeficiency virus (HIV) and hepatitis B virus (HBV) and is commonly used as part of antiretroviral therapy. The main limitation in the use of lamivudine is resistant mutation selection. Most of these mutations affect the YMDD motif of the HBV DNA polymerase. The resistance occurs through M550V or M550I aminoacid replacements. The M550V variation may be accompanied by L526M mutation, notably in HIV-HBV co-infected patients. The aim of… CONTINUE READING